AU2008214199A1 - Encapsulated picoplatin - Google Patents

Encapsulated picoplatin Download PDF

Info

Publication number
AU2008214199A1
AU2008214199A1 AU2008214199A AU2008214199A AU2008214199A1 AU 2008214199 A1 AU2008214199 A1 AU 2008214199A1 AU 2008214199 A AU2008214199 A AU 2008214199A AU 2008214199 A AU2008214199 A AU 2008214199A AU 2008214199 A1 AU2008214199 A1 AU 2008214199A1
Authority
AU
Australia
Prior art keywords
picoplatin
dosage form
unit dosage
cellulose
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008214199A
Other languages
English (en)
Inventor
Hazel B. Breitz
Alistair J. Leigh
Angelica Phillips
Christopher A. Procyshyn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Publication of AU2008214199A1 publication Critical patent/AU2008214199A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
AU2008214199A 2007-02-09 2008-02-08 Encapsulated picoplatin Abandoned AU2008214199A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US88920107P 2007-02-09 2007-02-09
US60/889,201 2007-02-09
US88967507P 2007-02-13 2007-02-13
US60/889,675 2007-02-13
US98415607P 2007-10-31 2007-10-31
US60/984,156 2007-10-31
US98902007P 2007-11-19 2007-11-19
US60/989,020 2007-11-19
PCT/US2008/001746 WO2008097658A1 (en) 2007-02-09 2008-02-08 Encapsulated picoplatin

Publications (1)

Publication Number Publication Date
AU2008214199A1 true AU2008214199A1 (en) 2008-08-14

Family

ID=39682045

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008214199A Abandoned AU2008214199A1 (en) 2007-02-09 2008-02-08 Encapsulated picoplatin

Country Status (12)

Country Link
US (2) US20100062056A1 (enExample)
EP (1) EP2109451A4 (enExample)
JP (1) JP2010518088A (enExample)
KR (2) KR20150125728A (enExample)
CN (1) CN101663040A (enExample)
AU (1) AU2008214199A1 (enExample)
BR (1) BRPI0806362A2 (enExample)
CA (1) CA2677639A1 (enExample)
IL (1) IL200261A0 (enExample)
MX (1) MX2009008487A (enExample)
RU (1) RU2009133447A (enExample)
WO (1) WO2008097658A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200920347A (en) * 2007-07-16 2009-05-16 Poniard Pharmaceuticals Inc Oral formulations for picoplatin
AU2009210654A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
US20120148661A1 (en) * 2009-04-15 2012-06-14 Poniard Pharmaceuticals, Inc. High bioavailability oral picoplatin anti-cancer therapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419340A (en) * 1969-03-24 1983-12-06 University Of Delaware Controlled release of anticancer agents from biodegradable polymers
US4302446A (en) * 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
JP2657393B2 (ja) * 1988-05-18 1997-09-24 日本化薬株式会社 化学塞栓療法剤
SK279684B6 (sk) * 1993-06-14 1999-02-11 Janssen Pharmaceutica N.V. Tableta a spôsob jej výroby
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9502799D0 (en) * 1995-02-14 1995-04-05 Johnson Matthey Plc Improvements in platinum complexes
DE19847618A1 (de) * 1998-10-15 2000-04-20 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US6894049B1 (en) * 2000-10-04 2005-05-17 Anormed, Inc. Platinum complexes as antitumor agents
SE0004671D0 (sv) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
JP2005502653A (ja) * 2001-08-20 2005-01-27 トランセーヴ・インコーポレーテッド 肺ガンの治療方法
WO2004054499A2 (en) * 2002-08-02 2004-07-01 Transave, Inc. Platinum aggregates and process for producing the same
AU2003261951A1 (en) * 2002-09-06 2004-03-29 D. Western Therapeutics Institute Medicinal composition and method for treating malignant tumor and utilization thereof
DE10325989A1 (de) * 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
WO2005077385A2 (en) * 2004-02-18 2005-08-25 Gpc Biotech Ag Methods for treating resistant or refractory tumors
DK1830817T3 (da) * 2004-12-30 2013-04-02 Pf Medicament Stabil, fast dispersion af et derivat af vinca-alkaloid og fremgangsmåde til fremstilling heraf
JP5106098B2 (ja) * 2005-02-28 2012-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の抗癌剤との新規併用
WO2006104668A2 (en) * 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
US8143236B2 (en) * 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) * 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US7687487B2 (en) * 2007-04-19 2010-03-30 Bionumerik Pharmaceuticals, Inc. Camptothecin-analog with a novel, “flipped” lactone-stable, E-ring and methods for making and using same
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
TW200920347A (en) * 2007-07-16 2009-05-16 Poniard Pharmaceuticals Inc Oral formulations for picoplatin
AU2009210654A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer

Also Published As

Publication number Publication date
WO2008097658A1 (en) 2008-08-14
CN101663040A (zh) 2010-03-03
BRPI0806362A2 (pt) 2011-09-06
US20130202690A1 (en) 2013-08-08
JP2010518088A (ja) 2010-05-27
RU2009133447A (ru) 2011-03-20
IL200261A0 (en) 2010-04-29
EP2109451A1 (en) 2009-10-21
US20100062056A1 (en) 2010-03-11
EP2109451A4 (en) 2012-12-19
KR20150125728A (ko) 2015-11-09
CA2677639A1 (en) 2008-08-14
MX2009008487A (es) 2010-01-15
KR20090109130A (ko) 2009-10-19

Similar Documents

Publication Publication Date Title
US20100062056A1 (en) Encapsulated picoplatin
ES2529570T3 (es) Formulaciones multiparticuladas de pantoprazol
EP1838617B1 (en) Calcium potassium ferrocyanide, a prophylactic mixture comprising this compound and the use thereof for decorporation of radiocesium in subjects affected by nuclear radiation
US20150196494A1 (en) Stabilized picoplatin oral dosage form
HK1206267A1 (en) Stabilized picoplatin oral dosage form
EA001760B1 (ru) Микрокапсулы, содержащие цис-платину
JPS63165318A (ja) 光の影響に対して安定化したニフェディピン濃縮物及びその製造方法
CN110520107A (zh) 用于局部肠递送的五氮杂大环状环配合物
NZ734043A (en) Compositions containing arsenic and their use in methods of treatment
ES2753435T3 (es) Composición farmacéutica que comprende capecitabina y ciclofosfamida
RU2343913C2 (ru) Фармацевтическая композиция, содержащая комплекс платины в качестве активного вещества, и способ ее получения
US20120148661A1 (en) High bioavailability oral picoplatin anti-cancer therapy
ES3048983T3 (en) A plurality of tasquinimod particles and use thereof
WO2001049269A1 (en) Sustained-releasing anthelmintic compositions comprising praziquantel
JP4707668B2 (ja) オキソプラチン、その塩および誘導体を含む医薬組成物
US12064507B2 (en) Composition and method for oral treatment of leukemia
CN101277681B (zh) 微管蛋白抑制剂吲地布林的口服固体药物制剂
HK1140131A (en) Stabilized picoplatin oral dosage form
CN1923281B (zh) 一种含植物生物碱的抗癌缓释注射剂
WO2022201087A1 (en) 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
CN113057949A (zh) 一种头孢拉定胶囊及其制备方法
NZ714554A (en) Pharmaceutical formulations of a hif hydroxylase inhibitor

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application